Tianda Pharmaceuticals Limited provided consolidated earnings guidance for the interim period ended June 30, 2023. For the period, the company expected the loss for the Current Interim Period would be reduced by over 70% from HKD 19.1 million in the Previous Interim Period. Excluding R&D expenses, the Group is expected to turnaround from a loss of HKD 7.1 million in the Previous Interim Period to a profit in the Current Interim Period.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.265 HKD | 0.00% | +1.92% | +21.56% |
1st Jan change | Capi. | |
---|---|---|
+21.56% | 72.78M | |
+25.83% | 661B | |
+27.42% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.96% | 231B | |
+5.26% | 200B | |
-9.24% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 455 Stock
- News Tianda Pharmaceuticals Limited
- Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023